Results 181 to 190 of about 27,465 (289)

A supramolecular assembly of cone‐specific G‐protein and cryptochrome 4a on lipid bilayer

open access: yesThe FEBS Journal, EarlyView.
Immobilized phospholipid bilayers on a sensor chip surface serve as membrane platform to investigate critical protein–lipid and protein–protein interaction processes by surface plasmon resonance. The putative magnetoreceptor cryptochrome 4a and the myristoylated cone‐specific G‐protein α‐subunit (Gtα) bind with high affinity to immobilized lipid ...
Ümmügülsüm Güzelsoy‐Flügge   +3 more
wiley   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska   +8 more
wiley   +1 more source

Untargeted Metabolomic and Lipidomic Profiles of Gingival Crevicular Fluid in the Context of Periodontitis

open access: yesJournal of Clinical Periodontology, EarlyView.
ABSTRACT Aim(s) This cross‐sectional clinical study aimed to explore the untargeted metabolomic and lipidomic profiles in gingival crevicular fluid (GCF) obtained from healthy individuals and patients with periodontitis. Materials and Methods GCF was collected from 17 periodontally healthy and 19 periodontitis patients.
Caroline H. Henderzahs   +6 more
wiley   +1 more source

Contractile Effects of Glucagon in Mouse Cardiac Preparations. [PDF]

open access: yesInt J Mol Sci
Neumann J   +6 more
europepmc   +1 more source

Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
We assessed four different doses of ME3183, a novel phosphodiesterase 4 inhibitor, and placebo in 132 patients with moderate to severe plaque psoriasis. At Week 16, more patients receiving ME3183 achieved ≥75% reduction in baseline Psoriasis Area and Severity Index scores than those receiving placebo, with no new safety concerns.
Kim A. Papp   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy